Inamed rejects mergers and repurchases stock:
This article was originally published in Clinica
Breast implant manufacturer Inamed has finished evaluating its strategic options - a process it began in early October - and plans to resume a $25 million stock repurchase programme. The company had received several enquiries regarding a merger (see Clinica No 930, p 11), but has now concluded that the indicated price ranges were insufficient. The Santa Barbara, California company had suspended the stock repurchase programme, which was authorised in September, pending the outcome of the evaluation process.